Lacking TNBC datasets that received immunotherapy, we selected three cohorts that received anti-PDL1, anti-PD1, and anti-MAGE-A3 therapy in bladder cancer (BLCA) and skin melanoma (SKCM) to verify the immunotherapy response prediction value of the TRG score. The gene discussed is MAGEA3; the disease is bladder transitional cell carcinoma.